Form 4: Ironwood Pharmaceuticals Director Jay Shepard Reports Grant of 45,000 Restricted Stock Units

Ironwood Pharmaceuticals, Inc. Director Jay Shepard has reported the acquisition of 45,000 shares of Class A Common Stock as a restricted stock grant, increasing his total beneficial ownership to 171,555 shares.

Summary

• Jay Shepard, a Director of Ironwood Pharmaceuticals, Inc. (IRWD), acquired 45,000 shares of Class A Common Stock on June 10, 2025.
• This acquisition was a grant of restricted stock at a price of $0 per share, indicating it was not a cash purchase.
• The grant was made pursuant to the company's Second Amended and Restated Non-employee Director Compensation Policy, which became effective on January 1, 2024.
• The restricted stock is scheduled to vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.
• Following this transaction, Jay Shepard's total beneficial ownership of Ironwood Pharmaceuticals' Class A Common Stock stands at 171,555 shares.

Sentiment

Score: 7

Explanation: The document reports a routine insider stock grant, which is generally a positive signal as it increases director ownership and aligns interests with shareholders. There are no negative financial or operational disclosures.

Positives

• The grant of restricted stock to Director Jay Shepard aligns his interests with long-term shareholder value, as the shares vest based on future tenure or performance.
• The increase in beneficial ownership by a director demonstrates continued confidence in the company's future prospects.

Risks

• The ultimate value of the granted restricted stock is directly tied to the future performance of Ironwood Pharmaceuticals' stock price, which is subject to market fluctuations and company-specific factors.

Future Outlook

The restricted stock grant is structured to vest in full on the date immediately preceding the next annual meeting of stockholders, linking the director's compensation to future company performance and governance cycles.

Industry Context

Insider stock grants are a common form of compensation for directors in the pharmaceutical and biotechnology industries, designed to align their long-term interests with the company's performance and shareholder returns. This filing represents a routine disclosure for a publicly traded company.

Comparison to Industry Standards

• The grant of restricted stock to non-employee directors is a standard practice across the pharmaceutical and broader public company landscape, aligning director incentives with shareholder value.
• The vesting schedule, tied to the next annual meeting, is a common approach for director equity awards, ensuring continued engagement and oversight.
• Companies such as Pfizer, Merck, and Johnson & Johnson also utilize equity-based compensation for their non-executive directors, often in the form of restricted stock units (RSUs) or stock options, with similar vesting conditions.

Corporate Governance

Stakeholder Impact

• Shareholders: The increased equity ownership by a director enhances the alignment of management interests with those of the shareholders.

Next Steps

• The restricted stock granted to Jay Shepard will vest on the date immediately preceding the next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Ironwood Pharmaceuticals, IRWD, Form 4, SEC filing, insider transaction, restricted stock, stock grant, director compensation, beneficial ownership, Jay Shepard